TABLE 5.
In vitro activity of cefepime-taniborbactam and comparator agents against carbapenem-resistant isolates of Enterobacterales and P. aeruginosa stratified by the presence and absence of molecularly identified carbapenemases
| Antimicrobial agent | No. (%) of susceptible isolates of: |
|||
|---|---|---|---|---|
| Carbapenem-resistant Enterobacterales (CRE) |
Carbapenem-resistant P. aeruginosa (CRPA) |
|||
| Without carbapenemase (n = 41) | With carbapenemase (n = 596) | Without carbapenemase (n = 753) | With carbapenemase (n = 249) | |
| Cefepime-taniborbactama | 39 (95.1) | 563 (94.5) | 714 (94.8) | 177 (71.1) |
| Ceftazidime-avibactam | 31 (79.5) | 345 (57.9) | 574 (76.2) | 36 (14.5) |
| Ceftolozane-tazobactam | 2 (4.9) | 5 (0.8) | 565 (75.0) | 2 (0.8) |
| Meropenem-vaborbactam | 37 (90.2) | 249 (41.8) | 365 (48.5) | 18 (7.2) |
| Piperacillin-tazobactam | 1 (2.4) | 0 (0) | 198 (26.3) | 8 (3.2) |
a
For comparative purposes only, percent susceptible and percent resistant for cefepime-taniborbactam correspond to the percentage of isolates inhibited at ≤16 μg/mL and ≥32 μg/mL, respectively.